Japanese CLL patients monitored for deep remission after venetoclax treatment
NCT ID NCT06362044
First seen Dec 12, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This study tracked 89 Japanese adults with chronic lymphocytic leukemia (CLL) who took venetoclax, sometimes with rituximab, for 24 months. Researchers measured how many patients had undetectable minimal residual disease (uMRD), a sign of deep remission. The goal was to understand real-world outcomes, not to test a new treatment. Participants followed their usual care, with no extra visits or procedures.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center Hospital East /ID# 265970
Kashiwa-shi, Chiba, 277-8577, Japan
Conditions
Explore the condition pages connected to this study.